ClinicalTrials.gg
CompletedNCT04800263Updated May 10, 2023

A Trial of SHR-1905 in Healthy Subjects

A Phase 1 interventional study of SHR-1905 and Placebo in Asthma, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-10.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
11th of 15
50 · median 84
Started
2021
with 4 others
Phase 1
7 of 15
1 open now
Registered
3rd of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 11th largest by enrollment, is one of 5 that started in 2021, is one of 7 in phase 1, and was the 3rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of subcutaneous administered SHR-1905 in healthy subjects.

Read the detailed description

The study will consist of one dose esclation part with a total of 5 dose levels. The Subjects will be randomized to receive SHR-1905 as reflected by the guiding principle for the dose esclation/expansion phase. Each dose group includes a screening period, a baseline period, an observational period, and a safety follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial.
  2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
  3. Total body weight ≥45 kg at screening, and (BMI) between 18 and 28 kg/m2 (inclusive).
  4. For healthy subjects, no abnormalities.
  5. Men and women of (WOCBP) must agree to take effective methods

Exclusion criteria

Exclusion Criteria:

  1. Known medical history of severe disease in cardiovascular, liver, kidney, digestive tract, mental nerve, hematology, metabolic disorders, etc.
  2. Severe injuries or major surgeries within 6 months before screening.
  3. Subjects with infecious disease.
  4. Hyper/Hypotension at screening and at check in.
  5. abnormalities in 12-Lead
  6. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening
  7. Positive urine drug screen .
  8. Subject who cannot perform venous blood sampling.
  9. Known history or suspected of being allergic to the study drugs and their .
  10. Use of any medicine within 4-weeks or within 5 half-lives
  11. History of alcohol abuse within 3 months prior to the IP administration .
  12. Participation in clinical trials of other drugs or medical devices within 3 months prior to screening
  13. in the investigator's judgment, may increase the risk to the subject
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    SHR-1905 Dose Level 1

    SHR-1905 Dose level 1

    Drug: SHR-1905 · Drug: Placebo

  • Experimental
    SHR-1905 Dose Level 2

    SHR-1905 Dose level 2

    Drug: SHR-1905 · Drug: Placebo

  • Experimental
    SHR-1905 Dose Level 3

    SHR-1905 Dose level 3

    Drug: SHR-1905 · Drug: Placebo

  • Experimental
    SHR-1905 Dose Level 4

    SHR-1905 Dose level 4

    Drug: SHR-1905 · Drug: Placebo

  • Experimental
    SHR-1905 Dose Level 5

    SHR-1905 Dose level 5

    Drug: SHR-1905 · Drug: Placebo

Interventions

  • SHR-1905 will be injected subcutaneously

  • DrugPlacebo

    Placebo will be injected subcutaneously

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence and severity of adverse events

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

Secondary outcomes

  1. Pharmacokinetics-AUC0-last

    Area under the concentration-time curve from time 0 to last time point after SHR-1905 administration

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  2. Pharmacokinetics-AUC0-inf

    Area under the concentration-time curve from time 0 to infinity after SHR-1905 administration

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  3. Pharmacokinetics-Tmax

    Time to Cmax of SHR-1905

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  4. Pharmacokinetics-Cmax

    Maximum observed concentration of SHR-1905

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  5. Pharmacokinetics-CL/F

    Apparent clearance of SHR-1905

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  6. Pharmacokinetics-Vz/F

    Apparent volume of distribution during terminal phase of SHR-1905

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  7. Pharmacokinetics-t1/2

    Terminal elimination half-life of SHR-1905

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  8. Anti-Drug antibody

    The percentage of subjects with positive ADA titers over time for SHR-1905

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

07

Study locations

1 site
  • Nucleus Network
    Brisbane, Queensland, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Nov 2022, 15 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 15 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 16, 2021
StartActual
Jul 27, 2021
Primary completionActual
Nov 12, 2022
CompletionActual
Nov 12, 2022
Last update
May 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04800263
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Jul 27, 2021
Primary completion
Nov 12, 2022
Completion
Nov 12, 2022
Last update
May 10, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion